These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29732928)

  • 41. Characteristics of trials and regulatory pathways leading to US approval of innovative vs. non-innovative oncology drugs.
    Vokinger KN; Kesselheim AS
    Health Policy; 2019 Aug; 123(8):721-727. PubMed ID: 31229275
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Matched analysis on orphan drug designations and approvals: cross regional analysis in the United States, the European Union, and Japan.
    Murakami M; Narukawa M
    Drug Discov Today; 2016 Apr; 21(4):544-9. PubMed ID: 26945941
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012.
    Pauwels K; Huys I; Casteels M; Larsson K; Voltz C; Penttila K; Morel T; Simoens S
    Orphanet J Rare Dis; 2017 Feb; 12(1):36. PubMed ID: 28209180
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expediting drug development--the FDA's new "breakthrough therapy" designation.
    Sherman RE; Li J; Shapley S; Robb M; Woodcock J
    N Engl J Med; 2013 Nov; 369(20):1877-80. PubMed ID: 24224621
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of Drug Lags in Development Initiation, New Drug Application and Approval Between Japan and the USA and the Impact of Local Versus Multi-regional Clinical Trials.
    Ushijima S; Matsumaru N; Tsukamoto K
    Pharmaceut Med; 2021 Jul; 35(4):253-260. PubMed ID: 34291425
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug Development, Trial Design, and Endpoints in Oncology: Adapting to Rapidly Changing Science.
    Blumenthal GM; Goldberg KB; Pazdur R
    Clin Pharmacol Ther; 2017 May; 101(5):572-574. PubMed ID: 28074476
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Trial Design and Efficacy Thresholds for Granting Breakthrough Therapy Designation in Oncology.
    Kern KA
    J Oncol Pract; 2016 Aug; 12(8):e810-7. PubMed ID: 27460496
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory Analysis.
    Tanaka M; Idei M; Sakaguchi H; Kato R; Sato D; Sawanobori K; Kawarasaki S; Hata T; Yoshizaki A; Nakamura M; Ikuma M
    Clin Pharmacol Ther; 2021 May; 109(5):1265-1273. PubMed ID: 33048367
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Investigating the landscape of US orphan product approvals.
    Miller KL; Lanthier M
    Orphanet J Rare Dis; 2018 Oct; 13(1):183. PubMed ID: 30348193
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Breakthrough therapy-designated oncology drugs: are they rightfully criticized?
    Mulder J; Pasmooij AMG; Stoyanova-Beninska VV; Schellens JHM
    Drug Discov Today; 2020 Sep; 25(9):1580-1584. PubMed ID: 32562841
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines.
    Hwang TJ; Franklin JM; Chen CT; Lauffenburger JC; Gyawali B; Kesselheim AS; Darrow JJ
    J Clin Oncol; 2018 Jun; 36(18):1805-1812. PubMed ID: 29688832
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Considerations and Regulatory Challenges for Innovative Medicines in Expedited Approval Programs: Breakthrough Therapy and Sakigake Designation.
    Kajiwara E; Shikano M
    Ther Innov Regul Sci; 2020 Jul; 54(4):814-820. PubMed ID: 32557300
    [TBL] [Abstract][Full Text] [Related]  

  • 53. End points and United States Food and Drug Administration approval of oncology drugs.
    Johnson JR; Williams G; Pazdur R
    J Clin Oncol; 2003 Apr; 21(7):1404-11. PubMed ID: 12663734
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of Addition of Indications for Antineoplastic Agents Approved in the United States and Japan from 2001 to 2020.
    Shizuya T; Miyazaki S
    Biol Pharm Bull; 2023; 46(7):987-996. PubMed ID: 37394648
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development Strategies.
    Zhou L; Higashimori M; Shen K; Zhang Z; Sheng J; Xu H; Horiuchi M; Ichikawa K; Al-Huniti N; Zhou D
    Clin Pharmacol Ther; 2019 Jun; 105(6):1303-1320. PubMed ID: 30802932
    [No Abstract]   [Full Text] [Related]  

  • 56. Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug development.
    Mease C; Miller KL; Fermaglich LJ; Best J; Liu G; Torjusen E
    Orphanet J Rare Dis; 2024 Feb; 19(1):86. PubMed ID: 38403586
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An appraisal of drug development timelines in the Era of precision oncology.
    Jardim DL; Schwaederle M; Hong DS; Kurzrock R
    Oncotarget; 2016 Aug; 7(33):53037-53046. PubMed ID: 27419632
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Achievements and challenges of the Sakigake designation system in Japan.
    Tanaka M; Idei M; Sakaguchi H; Kato R; Sato D; Sawanobori K; Kawarasaki S; Hata T; Yoshizaki A; Nakamura M; Ikuma M
    Br J Clin Pharmacol; 2021 Oct; 87(10):4027-4035. PubMed ID: 33694268
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
    Tsuji K; Tsutani K
    J Clin Pharm Ther; 2010 Jun; 35(3):289-301. PubMed ID: 20848767
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An Empirical Analysis of Japan's Drug Development Lag Behind the United States.
    Nakamura H; Wakutsu N; Murayama S; Suzuki T
    J Clin Pharmacol; 2022 Jul; 62(7):847-854. PubMed ID: 34970781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.